Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of 4-AP on Functional Recovery After Spinal Cord Injury
NCT05447676Phase 1Completed
- Sponsor
- Shirley Ryan AbilityLab
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dalfampridine in spinal cord injury (SCI) (3 arms), sponsored by Shirley Ryan AbilityLab. Primary endpoints: Transcranial Magnetic Evoked Potentials at 12 weeks and Maximum Voluntary Contraction at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
dalfampridine
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05447676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447676.